Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,030Revenue (TTM) $M181Net Margin (%)-74.4Altman Z-Score-2.7
Enterprise Value $M1,987EPS (TTM) $-1.0Operating Margin %-45.3Piotroski F-Score1
P/E(ttm)--Beneish M-Score16.7Pre-tax Margin (%)-74.1Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio5.1Cash flow > EarningsN
Price/Sales11.05-y EBITDA Growth Rate %-19.4Current Ratio5.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %-209.6ROA % (ttm)-28.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-426.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M136ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NKTRJoel Greenblatt 2015-09-30 Sold Out -0.14%$9.5 - $13.92
($11.79)
$ 14.9026%Sold Out0
NKTRJoel Greenblatt 2015-06-30 Buy 0.14%$9.52 - $13.84
($11.47)
$ 14.9030%New holding1,363,927
NKTRFirst Eagle Investment 2011-12-31 Sold Out -0.003%$4.22 - $5.62
($4.92)
$ 14.90203%Sold Out0
NKTRFirst Eagle Investment 2011-09-30 Buy $4.98 - $7.65
($5.97)
$ 14.90150%New holding125,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NKTR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Nicholson JohnSVP & CFO 2016-05-17Sell856$13.589.72view
ROBIN HOWARD WPresident & CEO 2016-05-17Sell2,170$13.589.72view
Doberstein Stephen KSVP & Chief Scientific Officer 2016-05-17Sell339$13.589.72view
Gergel Ivan P.SVP & Chief Medical Officer 2016-05-17Sell432$13.589.72view
Hora ManinderSVP Pharma Dev & Mfg Ops 2016-05-17Sell835$13.589.72view
Labrucherie Gil MSVP & General Counsel 2016-05-17Sell836$13.589.72view
Thomsen Jillian B.SVP & Chief Accounting Officer 2016-05-17Sell724$13.589.72view
Lingnau LutzDirector 2016-04-25Sell15,000$16.27-8.42view
Thomsen Jillian B.SVP & Chief Accounting Officer 2016-03-09Sell15,000$11.7926.38view
Gergel Ivan P.SVP & Chief Medical Officer 2016-02-17Sell556$11.9225view

Quarterly/Annual Reports about NKTR:

News about NKTR:

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics Feb 15 2016 
Weekly CEO Sells Highlight: Cadence Design Systems Inc., Nektar Therapeutics Inc., Netflix Inc., Pho Sep 27 2015 
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 

More From Other Websites
Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : May 25, 2016 May 25 2016
ETF’s with exposure to Nektar Therapeutics : May 20, 2016 May 20 2016
Nektar Therapeutics :NKTR-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
NEKTAR THERAPEUTICS Financials May 11 2016
Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : May 6, 2016 May 06 2016
NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report May 04 2016
ETF’s with exposure to Nektar Therapeutics : May 4, 2016 May 04 2016
Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss May 04 2016
Edited Transcript of NKTR earnings conference call or presentation 3-May-16 8:30pm GMT May 03 2016
Nektar Therapeutics Reports Financial Results for the First Quarter of 2016 May 03 2016
NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 03 2016
Nektar Therapeutics Reports Financial Results for the First Quarter of 2016 May 03 2016
Q1 2016 Nektar Therapeutics Earnings Release - After Market Close May 03 2016
Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close... Apr 28 2016
Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close... Apr 28 2016
Nektar Therapeutics Presents Pre-Clinical Data Combining NKTR 214 With Checkpoint Blockade Apr 18 2016
Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is... Apr 18 2016
Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is... Apr 18 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)